Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Immune checkpoint inhibitors (ICIs) have revolutionized the clinical management of multiple
tumours. However, only a few patients respond to ICIs, which has generated considerable …
tumours. However, only a few patients respond to ICIs, which has generated considerable …
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
I Otano, AC Ucero, J Zugazagoitia… - Nature reviews Clinical …, 2023 - nature.com
Non-small-cell lung cancer (NSCLC) has become a paradigm of precision medicine, with
the discovery of numerous disease subtypes defined by specific oncogenic driver mutations …
the discovery of numerous disease subtypes defined by specific oncogenic driver mutations …
MAPK inhibitor sensitivity scores predict sensitivity driven by the immune infiltration in pediatric low-grade gliomas
R Sigaud, TK Albert, C Hess, T Hielscher… - Nature …, 2023 - nature.com
Pediatric low-grade gliomas (pLGG) show heterogeneous responses to MAPK inhibitors
(MAPKi) in clinical trials. Thus, more complex stratification biomarkers are needed to identify …
(MAPKi) in clinical trials. Thus, more complex stratification biomarkers are needed to identify …
Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond
Y Zhao, J Du, X Shen - Frontiers in Immunology, 2023 - frontiersin.org
Myeloid-derived suppressor cells (MDSCs) are one of the major negative regulators in tumor
microenvironment (TME) due to their potent immunosuppressive capacity. MDSCs are the …
microenvironment (TME) due to their potent immunosuppressive capacity. MDSCs are the …
Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer
O Novoplansky, AB Shnerb, D Marripati… - Molecular …, 2023 - Wiley Online Library
Blocking the mitogen‐activated protein kinase (MAPK) pathway with the MEK1/2 inhibitor
trametinib has produced promising results in patients with head and neck squamous cell …
trametinib has produced promising results in patients with head and neck squamous cell …
[HTML][HTML] Unveiling the role of KRAS in tumor immune microenvironment
M Xu, X Zhao, T Wen, X Qu - Biomedicine & Pharmacotherapy, 2024 - Elsevier
Kirsten rats sarcoma viral oncogene (KRAS), the first discovered human oncogene, has long
been recognized as “undruggable”. KRAS mutations frequently occur in multiple human …
been recognized as “undruggable”. KRAS mutations frequently occur in multiple human …
Trametinib ameliorates aging-associated gut pathology in Drosophila females by reducing Pol III activity in intestinal stem cells
E Ureña, B Xu, JC Regan, ML Atilano… - Proceedings of the …, 2024 - National Acad Sciences
Pharmacological therapies are promising interventions to slow down aging and reduce
multimorbidity in the elderly. Studies in animal models are the first step toward translation of …
multimorbidity in the elderly. Studies in animal models are the first step toward translation of …
A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
X Peng, X Huang, TB Lulu, W Jia, S Zhang, L Cohen… - Molecular Cancer, 2024 - Springer
Abstract Background Phosphoinositide 3-kinases (PI3Ks) are critical regulators of diverse
cellular functions and have emerged as promising targets in cancer therapy. Despite …
cellular functions and have emerged as promising targets in cancer therapy. Despite …
Genomic and immunophenotypic landscape of acquired resistance to PD-(L) 1 blockade in non–small-cell lung cancer
PURPOSE Although immune checkpoint inhibitors (ICI) have extended survival in patients
with non–small-cell lung cancer (NSCLC), acquired resistance (AR) to ICI frequently …
with non–small-cell lung cancer (NSCLC), acquired resistance (AR) to ICI frequently …
ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework
At least 40% of human cancers are associated with aberrant ERK pathway activity (ERKp).
Inhibitors targeting various effectors within the ERKp have been developed and explored for …
Inhibitors targeting various effectors within the ERKp have been developed and explored for …